Schmidt‐Kraepelin 2013.

Trial name or title	Is an antipsychotic combination treatment of olanzapine and amisulpiride more effective than monotherapy.
Methods	Allocation: randomised. Blindness: double‐blind.
Participants	Diagnosis: schizophrenia or schizoaffective disorder. Expected sample size: 399. Age: 18‐65 years. History: no details.
Interventions	Combination therapy: olanzapine and amisulpiride. Monotherapy: olanzapine. Monotherapy: amisulpiride.
Outcomes	Symptomatic improvement of schizophrenia in comparison to time of inclusion of patient measured by PANSS. Serious adverse drug reactions. Change of clinical condition measured by CGI scale. Change of the subjective well‐being measured by SWN scale.
Starting date	June 2012.
Contact information	Joachim Cordes (joachim.cordes@lvr.de). Sandra Feyerabend (sandra.feyerabend@lvr.de).
Notes	ClinicalTrials.gov identifier: NCT01609153. DRKS‐ID: DRKS00003603. Sponsor: Heinrich‐Heine University, Duesseldor.

BPRS ‐ Brief Psychiatric Rating Scale
 BMI ‐ Body Mass Index
 CGI ‐ Clinical Global Impression
 CDSS ‐ Calgary Depression Scale for Schizophrenia
 ICD ‐ International Classification of Diseases
 PANSS ‐ Positive and Negative Syndrome Scale
 SAS ‐ Simpson Angus Scale
 SOFAS ‐ Social and Occupational Functioning Assessment Scale
 SWN ‐ Subjective Well Being under Neuroleptics